In November of 2014 Redpath Integrated Pathology was aquired by PDI, Inc. (NASDAQ: PDII). Redpath Integrated Pathology provides specialized cancer diagnostic testing and is one of the first commercial laboratories to integrate genomic analysis with everyday patient care. The company integrates traditional pathology practice with molecular genetic analysis. Using the firm's patented platform approach, PathfinderTG, the effort is to move from static to dynamic tissue analysis. Headed by personnel well known in both Gastrointestinal Pathology and Solid Tissue Molecular Pathology, RedPath 's approach begins and ends with an understanding and respect for the fundamentals of pathology practice. RedPath's introduction of new techniques and novel assays, along with the generation and parsing of complex information, effectively integrates a decade's advances in three fields: pathology, molecular analysis and information sciences.
